Needham & Company Reiterates Buy Rating on Avadel Pharmaceuticals (AVDL), Believes FDA Decision on FT218 Could be Coming Soon
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $15.00 price target on Avadel Pharmaceuticals (NASDAQ: AVDL), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
